Last reviewed 2026-04-23 · How we verify

RPV LA

RPV LA is a long-acting integrase inhibitor used to treat HIV-1 infection.

RPV LA is a long-acting integrase inhibitor used to treat HIV-1 infection. Used for Treatment of HIV-1 infection in adults and pediatric patients 3 months and older.

At a glance

Mechanism of action

It works by blocking the integrase enzyme, which is essential for the replication of the HIV-1 virus. This prevents the virus from integrating its genetic material into the host cell's DNA, thereby inhibiting viral replication.

Approved indications

• Treatment of HIV-1 infection in adults and pediatric patients 3 months and older

Common side effects

• Nausea
• Diarrhea
• Headache

Key clinical trials

• Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
• A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy (PHASE3)
• A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1 (PHASE3)
• Implementation of Long-acting Cabotegravir + Rilpivirine Administration Out of "HIV Units". (NA)
• Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs (PHASE2)
• More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents (PHASE1, PHASE2)
• Long-Acting Cabotegravir and Rilpivirine in People Living With HIV-1 Subtype A6: A Real-World Retrospective Study
• Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.